Immunic (IMUX) to Release Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is expected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 12:30 PM ET.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Trading Down 7.6%

Shares of IMUX opened at $0.69 on Wednesday. The stock’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.88. The firm has a market cap of $68.18 million, a P/E ratio of -0.74 and a beta of 1.56. Immunic has a 12 month low of $0.56 and a 12 month high of $1.42.

Hedge Funds Weigh In On Immunic

A hedge fund recently raised its stake in Immunic stock. Jane Street Group LLC raised its holdings in Immunic, Inc. (NASDAQ:IMUX) by 279.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 207,401 shares of the company’s stock after purchasing an additional 152,726 shares during the quarter. Jane Street Group LLC owned 0.22% of Immunic worth $226,000 as of its most recent SEC filing. 51.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IMUX has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, September 26th. Chardan Capital initiated coverage on Immunic in a research note on Monday, September 29th. They issued a “buy” rating and a $13.00 price target on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.